{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:55Z","timestamp":1787008675756,"version":"3.56.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"MINECO","doi-asserted-by":"publisher","award":["RYC2015-17519 and BIO2017-85329-R"],"award-info":[{"award-number":["RYC2015-17519 and BIO2017-85329-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The level of attrition on drug discovery, particularly at advanced stages, is very high due to unexpected adverse drug reactions (ADRs) caused by drug candidates, and thus, being able to predict undesirable responses when modulating certain protein targets would contribute to the development of safer drugs and have important economic implications. On the one hand, there are a number of databases that compile information of drug\u2013target interactions. On the other hand, there are a number of public resources that compile information on drugs and ADR. It is therefore possible to link target and ADRs using drug entities as connecting elements. Here, we present T-ARDIS (Target\u2014Adverse Reaction Database Integrated Search) database, a resource that provides comprehensive information on proteins and associated ADRs. By combining the information from drug\u2013protein and drug\u2013ADR databases, we statistically identify significant associations between proteins and ADRs. Besides describing the relationship between proteins and ADRs, T-ARDIS provides detailed description about proteins along with the drug and adverse reaction information. Currently T-ARDIS contains over 3000 ADR and 248 targets for a total of more 17\u2009000 pairwise interactions. Each entry can be retrieved through multiple search terms including target Uniprot ID, gene name, adverse effect and drug name. Ultimately, the T-ARDIS database has been created in response to the increasing interest in identifying early in the drug development pipeline potentially problematic protein targets whose modulation could result in ADRs.<\/jats:p>\n                  <jats:p>Database URL: http:\/\/www.bioinsilico.org\/T-ARDIS<\/jats:p>","DOI":"10.1093\/database\/baab068","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T08:38:54Z","timestamp":1633595934000},"source":"Crossref","is-referenced-by-count":14,"title":["Mining drug\u2013target and drug\u2013adverse drug reaction databases to identify target\u2013adverse drug reaction relationships"],"prefix":"10.1093","volume":"2021","author":[{"given":"Cristiano","family":"Galletti","sequence":"first","affiliation":[{"name":"Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Carrer Laura 13, Vic, Catalonia 08500, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Mirela","family":"Bota","sequence":"additional","affiliation":[{"name":"Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Carrer Laura 13, Vic, Catalonia 08500, Spain"},{"name":"Department of Experimental and Health Sciences, Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Experimental and Health Sciences, Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Catalonia 08003, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-1080","authenticated-orcid":false,"given":"Narcis","family":"Fernandez-Fuentes","sequence":"additional","affiliation":[{"name":"Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Carrer Laura 13, Vic, Catalonia 08500, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"2021102215042465900_R1","doi-asserted-by":"crossref","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Trans. Med. Commun."},{"key":"2021102215042465900_R2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2021102215042465900_R3","article-title":"Levelling the translational gap for animal to human efficacy data","volume":"10","author":"Ferreira","year":"2020","journal-title":"Animals (Basel)"},{"key":"2021102215042465900_R4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.drudis.2018.05.010","article-title":"Machine learning in chemoinformatics and drug discovery","volume":"23","author":"Lo","year":"2018","journal-title":"Drug Discov. Today"},{"key":"2021102215042465900_R5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","article-title":"Artificial intelligence for drug toxicity and safety","volume":"40","author":"Basile","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"2021102215042465900_R6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4155\/fmc.09.51","article-title":"In vitro safety pharmacology profiling: what else beyond hERG?","volume":"1","author":"Hamon","year":"2009","journal-title":"Future Med. Chem."},{"key":"2021102215042465900_R7","first-page":"717","article-title":"aer2vec: distributed representations of adverse event reporting system data as a means to identify drug\/side-effect associations","volume":"2019","author":"Portanova","year":"2019","journal-title":"AMIA Annu. Symp. Proc."},{"key":"2021102215042465900_R8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"2021102215042465900_R9","doi-asserted-by":"crossref","first-page":"D911","DOI":"10.1093\/nar\/gkx899","article-title":"ADReCS-Target: target profiles for aiding drug safety research and application","volume":"46","author":"Huang","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/acs.chemrestox.0c00294","article-title":"Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reports","volume":"34","author":"Smit","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"2021102215042465900_R11","doi-asserted-by":"crossref","DOI":"10.1038\/msb.2013.10","article-title":"Systematic identification of proteins that elicit drug side effects","volume":"9","author":"Kuhn","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"2021102215042465900_R12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/database\/bay083","article-title":"Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles","volume":"2018","author":"Tanoli","year":"2018","journal-title":"Database (Oxford)"},{"key":"2021102215042465900_R13","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","article-title":"STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data","volume":"44","author":"Szklarczyk","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pds.3805","article-title":"Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants","volume":"24","author":"Wong","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2021102215042465900_R15","volume-title":"MedEffect Canada - Adverse Reaction Database; editing status 2019-01-15; re3data.org - Registry of Research Data Repositories","author":"Canada H"},{"key":"2021102215042465900_R16","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003377","article-title":"Data-driven prediction of drug effects and interactions","volume":"4","author":"Tatonetti","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2021102215042465900_R18","article-title":"Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"key":"2021102215042465900_R19","doi-asserted-by":"crossref","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","author":"The UniProt C","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci. Data"},{"key":"2021102215042465900_R21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years","volume":"18","author":"Nelson","year":"2011","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"2021102215042465900_R22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/10543406.2013.736810","article-title":"Likelihood ratio test-based method for signal detection in drug classes using FDA\u2019s AERS database","volume":"23","author":"Huang","year":"2013","journal-title":"J. Biopharm. Stat."},{"key":"2021102215042465900_R23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102837","article-title":"Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology","volume":"57","author":"Ietswaart","year":"2020","journal-title":"EBioMedicine"},{"key":"2021102215042465900_R24","doi-asserted-by":"crossref","first-page":"D433","DOI":"10.1093\/nar\/gki005","article-title":"STRING: known and predicted protein-protein associations, integrated and transferred across organisms","volume":"33","author":"von Mering","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R25","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2020.108654","article-title":"Influence of multiple hypothesis testing on reproducibility in neuroimaging research: a simulation study and Python-based software","volume":"337","author":"Puoliv\u00e4li","year":"2020","journal-title":"J. Neurosci. Methods"},{"key":"2021102215042465900_R27","doi-asserted-by":"crossref","DOI":"10.1186\/s13321-020-00456-1","article-title":"An open source chemical structure curation pipeline using RDKit","volume":"12","author":"Bento","year":"2020","journal-title":"J. Cheminform."},{"key":"2021102215042465900_R28","doi-asserted-by":"crossref","first-page":"D330","DOI":"10.1093\/nar\/gky1055","article-title":"The gene ontology resource: 20 years and still GOing strong","volume":"47","author":"The Gene Ontology C","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021102215042465900_R29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/bioinformatics\/18.1.77","article-title":"Tolerating some redundancy significantly speeds up clustering of large protein databases","volume":"18","author":"Li","year":"2002","journal-title":"Bioinformatics"},{"key":"2021102215042465900_R30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2132","article-title":"Drugs, their targets and the nature and number of drug targets","volume":"5","author":"Imming","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021102215042465900_R31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1940-6207.CAPR-16-0094","article-title":"Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: implications for adenocarcinoma metastasis","volume":"9","author":"Boutaud","year":"2016","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"2021102215042465900_R32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.327.7415.572","article-title":"What are all the things that aspirin does?","volume":"327","author":"Flower","year":"2003","journal-title":"BMJ"},{"key":"2021102215042465900_R33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.2.4934.324-a","article-title":"Aspirin and ulcer","volume":"2","author":"Muir","year":"1955","journal-title":"Br. Med. J."},{"key":"2021102215042465900_R34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4166\/kjg.2016.67.6.300","article-title":"Nonsteroidal anti-inflammatory drug and aspirin-induced peptic ulcer disease","volume":"67","author":"Shim","year":"2016","journal-title":"Korean J. Gastroenterol."},{"key":"2021102215042465900_R35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/DHPS.S7634","article-title":"Antidepressant-associated sexual dysfunction: impact, effects, and treatment","volume":"2","author":"Higgins","year":"2010","journal-title":"Drug Healthcare Patient Saf."},{"key":"2021102215042465900_R36","article-title":"Budesonide-related adrenal insufficiency","volume":"2015","author":"Arntzenius","year":"2015","journal-title":"BMJ Case Rep."},{"key":"2021102215042465900_R37","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-20-1199","article-title":"Management of endocrine disease: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?","volume":"184","author":"Laugesen","year":"2021","journal-title":"Eur. J. Endocrinol."}],"container-title":["Database"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab068\/40823741\/baab068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab068\/40823741\/baab068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T11:08:38Z","timestamp":1634900918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/database\/article\/doi\/10.1093\/database\/baab068\/6408542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/database\/baab068","relation":{},"ISSN":["1758-0463"],"issn-type":[{"value":"1758-0463","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,10,1]]},"article-number":"baab068"}}